RecruitingPhase 2/3

Anticoagulation-free VV ECMO for Acute Respiratory Failure

Canada40 participantsStarted 2022-09-01

Plain-language summary

Currently international experts recommend therapeutic anticoagulation for veno-venous extracorporeal membrane oxygenation (VV-ECMO). Reports and case series suggest that the absence of therapeutic anticoagulation is safe for VV-ECMO. No randomized control trials have assessed this. The aim of this pilot study is to assess safety and feasibility of an "anticoagulation-free strategy" for veno-venous ECMO (VV-ECMO) in Acute respiratory distress syndrome (ARDS).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patient with ARDS on VV-ECMO Exclusion Criteria: * Contraindication to anticoagulation with UFH (known heparin-induced thrombocytopenia, active hemorrhage, any surgery precluding the use of anticoagulation), * Indication for therapeutic anticoagulation (pulmonary embolism or deep vein thrombosis, chronic anticoagulation therapy before ECMO insertion) * Low-flow (\<2 liters/min) VV-ECMO (ECCO2R)

What they're measuring

ECMO associated thrombotic complications

Timeframe: through ECMO completion, an average of 14 days

Trial details

NCT IDNCT04273607

SponsorDamian Ratano

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

Contact for this trial

Damian Ratano, MD

+1 416-340-3601 damian.ratano@chuv.ch

View on ClinicalTrials.gov More Extracorporeal Membrane Oxygenation Complication trials